AlphaQuest LLC Takes $548,000 Position in CG Oncology, Inc. $CGON

AlphaQuest LLC acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 13,600 shares of the company’s stock, valued at approximately $548,000.

Several other large investors have also recently added to or reduced their stakes in CGON. Voya Investment Management LLC increased its stake in CG Oncology by 217.6% during the 3rd quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock valued at $1,933,000 after buying an additional 32,877 shares during the period. CWM LLC boosted its holdings in shares of CG Oncology by 193.5% in the second quarter. CWM LLC now owns 6,193 shares of the company’s stock valued at $161,000 after acquiring an additional 4,083 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of CG Oncology during the second quarter valued at approximately $676,000. Franklin Resources Inc. lifted its position in CG Oncology by 12.7% in the second quarter. Franklin Resources Inc. now owns 1,486,839 shares of the company’s stock worth $38,658,000 after purchasing an additional 167,905 shares during the period. Finally, Tejara Capital Ltd acquired a new stake in CG Oncology in the second quarter worth approximately $944,000. 26.56% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James Mulay sold 11,145 shares of the business’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Leonard E. Post sold 1,000 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $41.43, for a total transaction of $41,430.00. The disclosure for this sale is available in the SEC filing. Insiders own 7.40% of the company’s stock.

CG Oncology Stock Performance

CG Oncology stock opened at $51.98 on Thursday. CG Oncology, Inc. has a 52 week low of $14.80 and a 52 week high of $57.88. The firm has a market capitalization of $4.19 billion, a price-to-earnings ratio of -25.48 and a beta of 1.32. The company has a 50 day moving average price of $46.07 and a 200 day moving average price of $38.82.

CG Oncology (NASDAQ:CGON) last released its earnings results on Friday, November 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.57). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.07 million. Equities analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Royal Bank Of Canada boosted their price objective on CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Wedbush assumed coverage on shares of CG Oncology in a report on Thursday, December 11th. They issued an “outperform” rating and a $70.00 price target for the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of CG Oncology in a research note on Monday, January 12th. Piper Sandler increased their target price on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.83.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.